Author:
Zahr Zaki Abou,Baer Alan N.
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Stertz G. Polymyositis. Berl Klin Wochenschr. 1916;53:489.
2. Buchbinder R, Hill CL. Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep. 2002;4(5):415–26.
3. Baer AN, Wortmann RL. The risk of malignancy in patients with dermatomyositis and polymyositis. In: Kagen LJ, editor. The Inflammatory Myopathies. New York: Humana Press; 2009. p. 307–18.
4. • Zhang W, Jiang SP, Huang L. Dermatomyositis and malignancy: a retrospective study of 115 cases. Eur Rev Med Pharmacol Sci. 2009;13(2):77-80. This was a retrospective review of 115 cases of cancer-associated DM seen at a tertiary medical center in Guangdong, China, between 1974 and 2008. Nasopharyngeal carcinoma constituted 51% of the associated malignancies.
5. • Prohic A, Kasumagic-Halilovic E, Simic D, et al. Clinical and biological factors predictive of malignancy in dermatomyositis. J Eur Acad Dermatol Venereol. 2009;23(5):591-2. The clinical and laboratory features of 32 patients with DM were reviewed in order to identify risk factors for associated cancer. Cutaneous necrosis and higher levels of muscle enzyme levels were significantly more common in the 8 patients with cancer than the 24 without cancer.
Cited by
129 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献